RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
2011-01-01 Cazzola, Mario
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
2011-01-01 DELLA PORTA, MATTEO GIOVANNI; Malcovati, Luca; Strupp, C; Ambaglio, I; Kuendgen, A; Zipperer, E; Travaglino, E; Invernizzi, Rosangela; Pascutto, C; Lazzarino, Mario; Germing, U; Cazzola, Mario
Role of ferritin and ferroportin genes in unexplained hyperferritinaemia
2005-01-01 Cazzola, Mario
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis
2013-01-01 Koreth, J; Pidala, J; Perez, Ws; Deeg, Hj; Garcia Manero, G; Malcovati, Luca; Cazzola, Mario; Park, S; Itzykson, R; Ades, L; Fenaux, P; Jadersten, M; Hellstrom Lindberg, E; Gale, Rp; Beach, Cl; Lee, Sj; Horowitz, Mm; Greenberg, Pl; Tallman, Ms; Dipersio, Jf; Bunjes, D; Weisdorf, Dj; Cutler, C.
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
2017-01-01 Verstovsek, S; Passamonti, F; Rambaldi, A; Barosi, G; Rumi, E; Gattoni, E; Pieri, L; Zhen, H; Granier, M; Assad, A; Cazzola, M; Kantarjian, Hm; Barbui, T; Vannucchi, Am.
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms
2019-01-01 Rumi, E; Zibellini, S; Boveri, E; Cavalloni, C; Riboni, R; Casetti, Ic; Ciboddo, M; Trotti, C; Favaron, C; Pietra, D; Candido, C; Ferretti, Vv; Cazzola, M; Arcaini, L.
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
2017-01-01 Pieri L1, 2; Paoli, C; Arena, U; Marra, F; Mori, F; Zucchini, M; Colagrande, S; Castellani, A; Masciulli, A; Rosti, V; De Stefano, V; Betti, S; Finazzi, G; Ferrari, Ml; Rumi, Elisa; Ruggeri, M; Nichele, I; Guglielmelli, P; Fjerza, R; Mannarelli, C; Fanelli, T; Merli, L; Corbizi Fattori, G; Massa, M; Cimino, G; Rambaldi, A; Barosi, G; Cazzola, Mario; Barbui, T; Vannucchi, Am
Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
1996-01-01 Bergamaschi, G; Perfetti, V; Tonon, L; Novella, A; Lucotti, C; Danova, M; Glennie, Mj; Merlini, Giampaolo; Cazzola, Mario
Scanning mutations of the 5'UTR regulatory sequence of L-ferritin by denaturing high-performance liquid chromatography: identification of new mutations
2003-01-01 Cremonesi, L; Paroni, R; Foglieni, B; Galbiati, S; Fermo, I; Soriani, N; Belloli, S; Ruggeri, G; Biasiotto, G; Cazzola, Mario; Ferrari, F; Ferrari, M; Arosio, P.
Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R)
2004-01-01 Roetto, A; Daraio, F; Porporato, P; Caruso, R; Cox, Tm; Cazzola, Mario; Gasparini, P; Piperno, A; Camaschella, C.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. | 1-gen-2011 | Cazzola, Mario | |
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome | 1-gen-2011 | DELLA PORTA, MATTEO GIOVANNI; Malcovati, Luca; Strupp, C; Ambaglio, I; Kuendgen, A; Zipperer, E; Travaglino, E; Invernizzi, Rosangela; Pascutto, C; Lazzarino, Mario; Germing, U; Cazzola, Mario | |
Role of ferritin and ferroportin genes in unexplained hyperferritinaemia | 1-gen-2005 | Cazzola, Mario | |
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis | 1-gen-2013 | Koreth, J; Pidala, J; Perez, Ws; Deeg, Hj; Garcia Manero, G; Malcovati, Luca; Cazzola, Mario; Park, S; Itzykson, R; Ades, L; Fenaux, P; Jadersten, M; Hellstrom Lindberg, E; Gale, Rp; Beach, Cl; Lee, Sj; Horowitz, Mm; Greenberg, Pl; Tallman, Ms; Dipersio, Jf; Bunjes, D; Weisdorf, Dj; Cutler, C. | |
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. | 1-gen-2017 | Verstovsek, S; Passamonti, F; Rambaldi, A; Barosi, G; Rumi, E; Gattoni, E; Pieri, L; Zhen, H; Granier, M; Assad, A; Cazzola, M; Kantarjian, Hm; Barbui, T; Vannucchi, Am. | |
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms | 1-gen-2019 | Rumi, E; Zibellini, S; Boveri, E; Cavalloni, C; Riboni, R; Casetti, Ic; Ciboddo, M; Trotti, C; Favaron, C; Pietra, D; Candido, C; Ferretti, Vv; Cazzola, M; Arcaini, L. | |
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms | 1-gen-2017 | Pieri L1, 2; Paoli, C; Arena, U; Marra, F; Mori, F; Zucchini, M; Colagrande, S; Castellani, A; Masciulli, A; Rosti, V; De Stefano, V; Betti, S; Finazzi, G; Ferrari, Ml; Rumi, Elisa; Ruggeri, M; Nichele, I; Guglielmelli, P; Fjerza, R; Mannarelli, C; Fanelli, T; Merli, L; Corbizi Fattori, G; Massa, M; Cimino, G; Rambaldi, A; Barosi, G; Cazzola, Mario; Barbui, T; Vannucchi, Am | |
Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. | 1-gen-1996 | Bergamaschi, G; Perfetti, V; Tonon, L; Novella, A; Lucotti, C; Danova, M; Glennie, Mj; Merlini, Giampaolo; Cazzola, Mario | |
Scanning mutations of the 5'UTR regulatory sequence of L-ferritin by denaturing high-performance liquid chromatography: identification of new mutations | 1-gen-2003 | Cremonesi, L; Paroni, R; Foglieni, B; Galbiati, S; Fermo, I; Soriani, N; Belloli, S; Ruggeri, G; Biasiotto, G; Cazzola, Mario; Ferrari, F; Ferrari, M; Arosio, P. | |
Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R) | 1-gen-2004 | Roetto, A; Daraio, F; Porporato, P; Caruso, R; Cox, Tm; Cazzola, Mario; Gasparini, P; Piperno, A; Camaschella, C. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 483
- 1 Contributo su Rivista::1.1 Arti... 469
- 1 Contributo su Rivista::1.5 Abst... 14
Data di pubblicazione
- 2020 - 2024 26
- 2010 - 2019 170
- 2000 - 2009 127
- 1990 - 1999 77
- 1980 - 1989 73
- 1974 - 1979 10
Editore
- Macmillan Magazines Limited:Porte... 4
- Blackwell Science Limited:PO Box ... 3
- American Society of Hematology:19... 2
- American Society for Biochemistry... 1
- Elsevier Science Incorporated / N... 1
- John Wiley & Sons Incorporated:Cu... 1
- Marcel Dekker Incorporated:270 Ma... 1
Rivista
- HAEMATOLOGICA 103
- BLOOD 96
- BRITISH JOURNAL OF HAEMATOLOGY 54
- LEUKEMIA 35
- AMERICAN JOURNAL OF HEMATOLOGY 17
- AMERICAN JOURNAL OF HEMATOLOGY 11
- JOURNAL OF CLINICAL ONCOLOGY 10
- SCANDINAVIAN JOURNAL OF HAEMATOLOGY 9
- THE NEW ENGLAND JOURNAL OF MEDICINE 9
- BLOOD 6
Keyword
- Myelodysplastic syndrome 60
- Anemia 45
- Iron 31
- Myeloproliferative neoplasm 28
- JAK2 22
- prognosis 19
- Erythropoietin 18
- Erythropoiesis 17
- mutation 17
- MYELODYSPLASTIC SYNDROME 17
Lingua
- eng 477
- ita 2
- spa 1
Accesso al fulltext
- no fulltext 483